FDA Continues Push To Bring Lab-Developed Tests Into The Fold
Executive Summary
In a Dec. 6 blog post, US FDA officials continued pressing for a new system of diagnostics regulation that puts laboratory-developed test services (LDTs) on the same footing as IVD test kits, all under a new framework where only about 10% of tests would require pre-market review.
You may also be interested in...
FDA Looks To Whittle Down Dx Review Load With Pre-Certs, Third-Party Assists
US FDA Commissioner Scott Gottlieb and the agency’s new diagnostics office chief Tim Stenzel want to use a combination of pre-certification, assistance from third-party reviewers and review exemptions to help quickly clear the tsunami of molecular-based diagnostic tests expected to be submitted to FDA for review in the next several years.
Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm
The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.
Labs, Test Makers Urge Congress To Pass Diagnostic Reforms
More than 80 industry, laboratory, health-care provider and patient groups sent a letter to two congressional committees, urging them to advance a bill to modernize the current way FDA regulates diagnostic tests, including possibly a new regulated product category that combines laboratory developed tests and in vitro diagnostics.